Articular Cartilage: Where it all started
Articular cartilage is a smooth white tissue that covers the ends of bones where they join together. It is essential for maintaining the mobility of bone joints. However, despite this important role, the tissue is susceptible to degeneration caused by trauma, disease or ageing. This can lead to conditions such as osteoarthritis, which can cause chronic pain and, in some cases, disability (Cui et al., 2020).
Reversing damage to articular cartilage remains a great challenge in musculoskeletal medicine. One way to tackle this issue is to better understand how articular cartilage forms during embryonic development, as this knowledge could help researchers to develop new methods for rebuilding cartilage. Yet, the origins of the main cells in cartilage, known as articular chondrocytes, and the identity of the genes that regulate their production remain unclear. Now, in eLife, Xianpeng Ge (Capital Medical University in Beijing) and colleagues – including Fan Zhang and Yuanyuan Wang as joint first authors – report new insights into the formation of articular chondrocytes (Zhang et al., 2023).
Previous research has shown that the gene NFATc1 helps to regulate the development of bones by controlling cells that absorb and form bone (Winslow et al., 2006). To find out if NFATc1 could also be involved in cartilage development, Zhang et al. used genetically modified mouse embryos, in which cells expressing NFATc1 were tagged with a fluorescent marker that allowed the researchers to track these cells and their offspring over time. This revealed that NFATc1 is expressed in a group of progenitor cells throughout embryonic and even postnatal development, and that these cells are responsible for generating most of the articular chondrocytes (Figure 1).
Further experiments in cells and embryonic mice revealed that the expression of NFATc1 decreased as the articular chondrocytes matured. Zhang et al. found that when the gene was removed from the cartilage progenitors, the maturation of chondrocytes was faster and the formation of articular cartilage in embryos was still supported. Consistent with this, when NFATc1 was overactivated, the progenitor cells could no longer mature into chondrocytes. This indicates that this gene negatively regulates the development of articular chondrocytes.
So far, it has been challenging to track how articular cartilage develops as most genetic markers cannot distinguish between the different cell types in the relevant tissues (Rux et al., 2019; Chijimatsu and Saito, 2019). The only exception is the gene Prg4, a widely used marker of articular cartilage progenitors. But since cells only start to express this gene at a later stage during development, the marker fails to track their movement during the earlier stages (Kozhemyakina et al., 2015). In contrast, NFATc1 is expressed early during articular cartilage development, and may therefore offer a better alternative for studying the origin of articular cartilage.
It was previously thought that NFATc1, together with another gene involved in cartilage formation, NFATc2, restricts the overgrowth of cartilage (also known as osteochondroma) at the sites where the ligaments insert into the bone. However, adjusting how much of either of those genes was removed from the mice’s progenitor cells could in fact determine the number and size of osteochondromas (Ge et al., 2016). This knowledge may be helpful in understanding how NFATc1 may suppress the formation of cartilage in certain diseases.
It has been suggested that both NFATc1 and NFATc2 are key suppressors of osteoarthritis, which is crucial for articular cartilage formation in mice (Greenblatt et al., 2013). However, when Zhang et al. used a different approach to delete these two genes, they observed the opposite effect – removing NFATc1 and NFATc2 enhanced chondrogenesis under pathological conditions. This suggests that researchers should carefully consider the genetic ablating tools they use when studying the role of progenitor cells in articular cartilage.
Moreover, it has been shown that adult skeletal stem cells expressing NFATc1 behave as bone-cell progenitors and contribute to the early stages of repair following a bone fracture (Yu et al., 2022). This highlights the complex pool of progenitor cells that express NFATc1, and how the fate of these progenitors changes during different periods of development as well as adulthood. More importantly, to date, it remains unclear whether these NFATc1-expressing progenitor cells fulfill stemness criteria in the skeleton, such as stem-cell transplantation (Debnath et al., 2018), or if these cells are able to generate functional articular cartilage.
Despite a lack of evidence confirming the stemness of NFATc1-expressing progenitor cells, the work of Zhang et al. offers researchers an additional genetic tool to detect and track the origins of articular chondrocytes. Moreover, their findings provide valuable insights into the mechanism of articular cartilage formation. If studies in human cells achieve similar results, this may help scientists to identify potential treatments of cartilage diseases, such as osteoarthritis.
References
-
Mechanisms of synovial joint and articular cartilage developmentCellular and Molecular Life Sciences 76:3939–3952.https://doi.org/10.1007/s00018-019-03191-5
-
Identification of a Prg4-expressing articular cartilage progenitor cell population in miceArthritis & Rheumatology 67:1261–1273.https://doi.org/10.1002/art.39030
-
Joints in the appendicular skeleton: developmental mechanisms and evolutionary influencesCurrent Topics in Developmental Biology 133:119–151.https://doi.org/10.1016/bs.ctdb.2018.11.002
-
Calcineurin/NFAT signaling in osteoblasts regulates bone massDevelopmental Cell 10:771–782.https://doi.org/10.1016/j.devcel.2006.04.006
Article and author information
Author details
Publication history
Copyright
© 2023, Zhang et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 598
- views
-
- 63
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Medicine
- Neuroscience
Background:
Subarachnoid hemorrhage (SAH) is characterized by intense central inflammation, leading to substantial post-hemorrhagic complications such as vasospasm and delayed cerebral ischemia. Given the anti-inflammatory effect of transcutaneous auricular vagus nerve stimulation (taVNS) and its ability to promote brain plasticity, taVNS has emerged as a promising therapeutic option for SAH patients. However, the effects of taVNS on cardiovascular dynamics in critically ill patients, like those with SAH, have not yet been investigated. Given the association between cardiac complications and elevated risk of poor clinical outcomes after SAH, it is essential to characterize the cardiovascular effects of taVNS to ensure this approach is safe in this fragile population. Therefore, this study assessed the impact of both acute and repetitive taVNS on cardiovascular function.
Methods:
In this randomized clinical trial, 24 SAH patients were assigned to either a taVNS treatment or a sham treatment group. During their stay in the intensive care unit, we monitored patient electrocardiogram readings and vital signs. We compared long-term changes in heart rate, heart rate variability (HRV), QT interval, and blood pressure between the two groups. Additionally, we assessed the effects of acute taVNS by comparing cardiovascular metrics before, during, and after the intervention. We also explored acute cardiovascular biomarkers in patients exhibiting clinical improvement.
Results:
We found that repetitive taVNS did not significantly alter heart rate, QT interval, blood pressure, or intracranial pressure (ICP). However, repetitive taVNS increased overall HRV and parasympathetic activity compared to the sham treatment. The increase in parasympathetic activity was most pronounced from 2 to 4 days after initial treatment (Cohen’s d = 0.50). Acutely, taVNS increased heart rate, blood pressure, and peripheral perfusion index without affecting the corrected QT interval, ICP, or HRV. The acute post-treatment elevation in heart rate was more pronounced in patients who experienced a decrease of more than one point in their modified Rankin Score at the time of discharge.
Conclusions:
Our study found that taVNS treatment did not induce adverse cardiovascular effects, such as bradycardia or QT prolongation, supporting its development as a safe immunomodulatory treatment approach for SAH patients. The observed acute increase in heart rate after taVNS treatment may serve as a biomarker for SAH patients who could derive greater benefit from this treatment.
Funding:
The American Association of Neurological Surgeons (ALH), The Aneurysm and AVM Foundation (ALH), The National Institutes of Health R01-EB026439, P41-EB018783, U24-NS109103, R21-NS128307 (ECL, PB), McDonnell Center for Systems Neuroscience (ECL, PB), and Fondazione Neurone (PB).
Clinical trial number:
-
- Immunology and Inflammation
- Medicine
Together with obesity and type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global epidemic. Activation of the complement system and infiltration of macrophages has been linked to progression of metabolic liver disease. The role of complement receptors in macrophage activation and recruitment in MASLD remains poorly understood. In human and mouse, C3AR1 in the liver is expressed primarily in Kupffer cells, but is downregulated in humans with MASLD compared to obese controls. To test the role of complement 3a receptor (C3aR1) on macrophages and liver resident macrophages in MASLD, we generated mice deficient in C3aR1 on all macrophages (C3aR1-MφKO) or specifically in liver Kupffer cells (C3aR1-KpKO) and subjected them to a model of metabolic steatotic liver disease. We show that macrophages account for the vast majority of C3ar1 expression in the liver. Overall, C3aR1-MφKO and C3aR1-KpKO mice have similar body weight gain without significant alterations in glucose homeostasis, hepatic steatosis and fibrosis, compared to controls on a MASLD-inducing diet. This study demonstrates that C3aR1 deletion in macrophages or Kupffer cells, the predominant liver cell type expressing C3ar1, has no significant effect on liver steatosis, inflammation or fibrosis in a dietary MASLD model.